|Articles|June 29, 2018
Korean Biotech Talks About U.S. Company Launch
Author(s)Michelle Maskaly
Enzychem Lifesciences explains why the Korean biotech decided to open U.S. headquarters, as well as gives an update on their most recent clinical trials.
Advertisement
Enzychem Lifesciences’ Chairman and CEO, Ki-Young Sohn explains why the Korean biotech decided to open U.S. headquarters, as well as gives an update on their most recent clinical trials.
He spoke to Pharm Exec during a company event in New York City.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Economics of the 340B Drug Pricing Program: Strategic Imperatives for the Life Sciences Industry in 2026
2
How 3D Printing Speeds Up Drug Production
3
Pharmaceutical Executive Daily: FDA Pilot Targets Faster Early-Stage Drug Trial Starts
4
FDA Pilot Targets Faster Early-Stage Drug Trial Starts
5